TARA Working Prototype Engagement Evaluation: Feasibility Study
Primary Purpose
Pulmonary Disease, Chronic Obstructive
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Digital Behaviour Change Intervention
Sponsored by
About this trial
This is an interventional device feasibility trial for Pulmonary Disease, Chronic Obstructive
Eligibility Criteria
Inclusion Criteria:
- Signed and dated written electronic informed consent (e-consent) in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the study
- Male or female patients
- All patients must have a self-reported confirmation of a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD)(or chronic bronchitis or emphysema)
- Age ≥ 40 years
- Patients must be current or ex-smokers with a smoking history of at least 10 pack-years (pack years = [cigarettes per day/20] x years of smoking)
- Modified Medical Research Council (mMRC) Score ≥ 1 (i.e. evidence of activity-related breathlessness)
- Patients must have a current prescription for once daily maintenance bronchodilator in keeping with their approved labels as well as a short-acting bronchodilator ("rescue medication") for at least 3 months prior to study enrolment
- Participants must be willing to use a smart watch and be willing to complete all data collection requirements (within TARA plus phone interview plus on-line questionnaires)
- Patients must confirm that his/her treating physician has been informed about the patient's participation in the study (prior to TARA log-in)
- Fluency in written English
- Currently residing in US (for duration of study)
- Not fully adherent (self-report) to once daily inhaled COPD medication (<80% on a protocol-specific participant self-assessment scale of medication adherence (0 - 100%))
- Access to (and comfort with) a digital device (Desktop; Laptop; Tablet), with updated Firefox [version 67.0 and above] or Chrome [version 75.0.3770.80 and above] browsers installed (or willing to download up-to-date version for the study), and daily home access to internet
- Need to have personal e-mail account that is used daily
Exclusion Criteria:
- Patients with asthma
- Patients who are currently prescribed oxygen therapy
- Patients who have completed a pulmonary rehabilitation (PR) program in the 6 weeks prior to enrolment or patients who are currently in a PR program (rationale: PR programs typically include a self-management component which may interfere with study objectives)
- Planned vacation period during the study period that requires overnight stays away from home
- Major surgery performed within 6 weeks prior to enrolment or planned within 2 months after enrolment, e.g. hip replacement
- Previous enrolment in this study
- Currently enrolled in another investigational device or drug study/trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s)
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Current use of a Smartwatch and/or wrist-worn step counter and not willing to switch to the study-specific Smartwatch for the duration of study
- Any medical or neuro-cognitive condition that would limit the ability of the participant to consent
- Further exclusion criteria apply
Sites / Locations
- Medullan
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
All subjects
Arm Description
Outcomes
Primary Outcome Measures
% of study participants achieving 80% or higher engagement score with their personal TARA program
Study participant's motivation to engage with the TARA working prototype (version 1) and their perceptions of value and usefulness
Qualitative assessment of motivation and perceptions of value and usefulness at different stages in the participant's journey through the prototype; data sourced via discussion in an exit interview at the end of the study.
Evidence of usability issues, patterns of dis-engagement or failures of use in particular pages or functional areas of the prototype
Analysis of usage data of the site to explore if there are common points at which participants fail to progress, make mistakes or abandon interactions; Data will be sourced from individual and amalgamated usage analytics - data points will include drop-out rates for each of the main functional areas of the site and will be supplemented by within-page usage data An overall score for perceived ease-of-use will be generated using the 'System Usability Scale' (SUS), using self-reported data from the pre- and post-TARA participant questionnaire
Study participant's reports of usability or other issues from using the prototype
Secondary Outcome Measures
% of study participants who achieve a score of 8 or greater in Knowledge, Motivation, Confidence (KMC) assessments
% of study participants who achieve a positive change in measures of motivation, activation, competence (self-efficacy) and stage of change
% of study participants who report increases in adherence to once daily inhaled medication and reduction in Chronic Obstructive Pulmonary Disease (COPD) symptoms
Full Information
NCT ID
NCT04085302
First Posted
September 3, 2019
Last Updated
September 10, 2020
Sponsor
Boehringer Ingelheim
1. Study Identification
Unique Protocol Identification Number
NCT04085302
Brief Title
TARA Working Prototype Engagement Evaluation: Feasibility Study
Official Title
Mixed Methods (Quantitative, Qualitative) Feasability Study Assessing Engagement With the First Version of the TARA Working Prototype (a Digital Behaviour Change Intervention, DBCI) in Individuals With COPD
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
September 26, 2019 (Actual)
Primary Completion Date
December 3, 2019 (Actual)
Study Completion Date
December 3, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
TARA is a Digital Behaviour Change Intervention (DBCI) for individuals with Chronic Obstructive Pulmonary Disease (COPD)(IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology. HCD involves, among other elements, members of the target audience in evaluations at multiple stages within the design process.
This feasibility study is primarily designed to assess the acceptability of the DBCI test asset to the target audience. Acceptability as defined for the purpose of this study includes usability of the system, and perceived value and desirability to the end-user audience. As such, engagement in this context is deemed to mean the degree to which the test asset provides a usable, acceptable, desirable and valuable experience to its users during a time-limited trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
All subjects
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Digital Behaviour Change Intervention
Intervention Description
14 days
Primary Outcome Measure Information:
Title
% of study participants achieving 80% or higher engagement score with their personal TARA program
Time Frame
Up to 14 days
Title
Study participant's motivation to engage with the TARA working prototype (version 1) and their perceptions of value and usefulness
Description
Qualitative assessment of motivation and perceptions of value and usefulness at different stages in the participant's journey through the prototype; data sourced via discussion in an exit interview at the end of the study.
Time Frame
Up to 14 days
Title
Evidence of usability issues, patterns of dis-engagement or failures of use in particular pages or functional areas of the prototype
Description
Analysis of usage data of the site to explore if there are common points at which participants fail to progress, make mistakes or abandon interactions; Data will be sourced from individual and amalgamated usage analytics - data points will include drop-out rates for each of the main functional areas of the site and will be supplemented by within-page usage data An overall score for perceived ease-of-use will be generated using the 'System Usability Scale' (SUS), using self-reported data from the pre- and post-TARA participant questionnaire
Time Frame
Up to 14 days
Title
Study participant's reports of usability or other issues from using the prototype
Time Frame
Up to 14 days
Secondary Outcome Measure Information:
Title
% of study participants who achieve a score of 8 or greater in Knowledge, Motivation, Confidence (KMC) assessments
Time Frame
Up to 14 days
Title
% of study participants who achieve a positive change in measures of motivation, activation, competence (self-efficacy) and stage of change
Time Frame
Up to 14 days
Title
% of study participants who report increases in adherence to once daily inhaled medication and reduction in Chronic Obstructive Pulmonary Disease (COPD) symptoms
Time Frame
Up to 14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed and dated written electronic informed consent (e-consent) in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the study
Male or female patients
All patients must have a self-reported confirmation of a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD)(or chronic bronchitis or emphysema)
Age ≥ 40 years
Patients must be current or ex-smokers with a smoking history of at least 10 pack-years (pack years = [cigarettes per day/20] x years of smoking)
Modified Medical Research Council (mMRC) Score ≥ 1 (i.e. evidence of activity-related breathlessness)
Patients must have a current prescription for once daily maintenance bronchodilator in keeping with their approved labels as well as a short-acting bronchodilator ("rescue medication") for at least 3 months prior to study enrolment
Participants must be willing to use a smart watch and be willing to complete all data collection requirements (within TARA plus phone interview plus on-line questionnaires)
Patients must confirm that his/her treating physician has been informed about the patient's participation in the study (prior to TARA log-in)
Fluency in written English
Currently residing in US (for duration of study)
Not fully adherent (self-report) to once daily inhaled COPD medication (<80% on a protocol-specific participant self-assessment scale of medication adherence (0 - 100%))
Access to (and comfort with) a digital device (Desktop; Laptop; Tablet), with updated Firefox [version 67.0 and above] or Chrome [version 75.0.3770.80 and above] browsers installed (or willing to download up-to-date version for the study), and daily home access to internet
Need to have personal e-mail account that is used daily
Exclusion Criteria:
Patients with asthma
Patients who are currently prescribed oxygen therapy
Patients who have completed a pulmonary rehabilitation (PR) program in the 6 weeks prior to enrolment or patients who are currently in a PR program (rationale: PR programs typically include a self-management component which may interfere with study objectives)
Planned vacation period during the study period that requires overnight stays away from home
Major surgery performed within 6 weeks prior to enrolment or planned within 2 months after enrolment, e.g. hip replacement
Previous enrolment in this study
Currently enrolled in another investigational device or drug study/trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s)
Women who are pregnant, nursing, or who plan to become pregnant while in the trial
Current use of a Smartwatch and/or wrist-worn step counter and not willing to switch to the study-specific Smartwatch for the duration of study
Any medical or neuro-cognitive condition that would limit the ability of the participant to consent
Further exclusion criteria apply
Facility Information:
Facility Name
Medullan
City
Somerville
State/Province
Massachusetts
ZIP/Postal Code
02144
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: http://trials.boehringer-ingelheim.com/
Learn more about this trial
TARA Working Prototype Engagement Evaluation: Feasibility Study
We'll reach out to this number within 24 hrs